-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Advances in cancer screening methods have opened the way for accidental discovery and overdiagnosis of cancer.
We conducted a second analysis of the National Lung Screening Trial (registered 2002-2004), a randomized controlled trial that compared low-dose computerized fault scans (LDCT; n s 26,722) and chest X-ray photography (CXR; n s 26,732) to detect lung cancer to detect accidental findings related to thyroid cancer (ThCa).
study included three rounds of screening, with a medium follow-up time of 6.6 years for LDCT and 6.5 years for CXR.
radiologists reported lung and non-lung-related abnormalities.
In baseline, year 1 and year 2, 5.7 percent, 4.7 percent, and 4.5 percent of participants in the LDCT group detected abnormalities above the shin muscle (AADs), while the CXR group detected abnormalities above the muscle (AADs), while the CXR group detected 2.3 percent, 1.5 percent, and 1.3 percent, respectively.
the LDCT group, 205 AADs (7.0%) were associated with the thyroid gland.
, 60 ThCas, 35 LDCT and 25 CXR (P-0.2) were studied.
LDCT group, participants with previous AAD had a 7.8-fold increased risk of ThCa (95% confidence interval: 4.0, 15.1) compared to participants without AAD.
ThCas early and persistent overdoses diagnosed earlier in the LDCT group suggest overdiagnosis.
early detection of lung cancer using sensitive screening methods may be accompanied by the discovery of thyroid tumors.
.
